Computational study on gabapentin as a potential therapy for partial seizures
1 Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India.
2 Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India-110062.
3 College of Business, British University of Bahrain, Bahrain.
Review
World Journal of Biology Pharmacy and Health Sciences, 2022, 12(03), 025–032.
Article DOI: 10.30574/wjbphs.2022.12.3.0204
Publication history:
Received on 16 October 2022; revised on 27 November 2022; accepted on 30November 2022
Abstract:
US Food and Drug Administration (USFDA) approved gabapentin as an adjuvant treatment for refractory partial seizures and several diverse disorders. The drug has a relatively safe profile and is well tolerated; however, awareness is required to monitor the patient's medication, its misuse, and how to approach better patient fate. Despite the enormous scientific hypothesis encircling the drug, there is a requisite to research further about the novelty of the drug.
The review delineates the drug profile, synthesis, pharmacology, ADME properties, and computational study of gabapentin.
Keywords:
Gabapentin; Anticonvulsants; Synthesis; Molecular docking; Spectral information
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0